Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The CYP2C19 enzyme polymorphism.

P J Wedlund1

  • 1College of Pharmacy and Eastern State Hospital Research Center, University of Kentucky, Lexington, KY 40536-0082, USA.

Pharmacology
|September 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.

Pharmacopsychiatry·2007
Same author

CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing.

The pharmacogenomics journal·2006
Same author

Pharmacogenomic testing: the cost factor.

The pharmacogenomics journal·2002
Same author

Racial differences in parathyroid hormone levels in patients with secondary hyperparathyroidism.

Clinical nephrology·2002
Same author

[Distinguishing CYP2D6 homozygous and heterozygous extensive metabolizers by dextromethorphan phenotyping].

Yao xue xue bao = Acta pharmaceutica Sinica·2001
Same author

Practical considerations for pharmacogenetic testing.

MLO: medical laboratory observer·2001
Same journal

Safety and efficacy of Efbemalenograstim alfa for patients at risk for chemotherapy-induced neutropenia: A Systematic review and Meta-analysis.

Pharmacology·2026
Same journal

Retraction Statement.

Pharmacology·2026
Same journal

Antiplatelet Therapy After Endovascular Intracranial Aneurysm Surgery: Comparative Effectiveness and Safety Insights from Systematic Review and Meta-Analysis.

Pharmacology·2026
Same journal

Ciprofol versus Propofol for General Anesthesia Induction in Major Orthopedic Surgery: Efficacy and Safety Analyses Pertaining to Anesthetic Parameters.

Pharmacology·2026
Same journal

Sappanone A targets TFEB to promote lysosomal autophagy and attenuate high glucose-induced myocardial injury.

Pharmacology·2026
Same journal

Tocilizumab Biosimilars Versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity.

Pharmacology·2026
See all related articles

Genetic testing for CYP2C19 polymorphism is replacing probe drugs. More research is needed to understand its clinical relevance and impact on drug toxicity and patient outcomes.

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Clinical Pharmacology

Background:

  • CYP2C19 polymorphism is increasingly screened using genetic tests, moving beyond traditional probe drugs.
  • Current understanding of the clinical and toxicological significance of CYP2C19 genetic variations remains limited.
  • The need for comprehensive research to fully elucidate the population-level importance of this genetic factor is evident.

Purpose of the Study:

  • To highlight the growing role of genetic testing for CYP2C19 polymorphism.
  • To identify areas requiring further investigation regarding CYP2C19's clinical and toxicological relevance.
  • To emphasize the necessity of integrated research approaches for a complete understanding.

Main Methods:

  • Review of current practices in population screening for CYP2C19 polymorphism.

Related Experiment Videos

  • Discussion of potential benefits of 3-D enzyme models for substrate identification.
  • Call for clinical studies to assess therapeutic outcomes and drug toxicity in patient populations.
  • Integration of molecular modeling, genetic testing, and clinical/epidemiological research.

    • Main Results:

    • Genetic testing is emerging as the primary method for CYP2C19 polymorphism screening.
    • Significant gaps exist in the knowledge of CYP2C19's clinical and toxicological impact.
    • 3-D modeling offers a potential avenue for automating and accelerating CYP2C19 substrate identification.
    • Clinical research is essential to validate the effects of CYP2C19 polymorphism on patient drug response.

    Conclusions:

    • Further research integrating molecular modeling, genetic testing, and clinical studies is crucial.
    • A deeper appreciation of CYP2C19's population-wide significance requires a multidisciplinary approach.
    • Understanding CYP2C19 genetic variations is key to optimizing drug therapy and minimizing toxicity.